Shanghai Junshi Biosciences Co., Ltd. announced that Following the election of Dr. Li Ning ("Dr. Li") as vice chairman of the Board, Dr. Li will cease to be the chief executive officer of the Company. Dr. Li has confirmed that he has no disagreement with the Board, and there are no other matters that should be brought to the attention of the Shareholders in relation thereto. The role of general manager and chief executive officer of the Company will be assumed by Dr. Zou as approved by the Board with effect from the date of this announcement to the conclusion of the term of the third session of the Board.

She shall be responsible for the overall work of the Company. Dr. Zou Jianjun aged 52, has been an executive Director since June 2022. From April 2022 to January 2024, she served as the deputy general manager and global research and development president of the Company.

From August 1995 to September 2005, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People 's Liberation Armyand at the department of oncology at the Shanghai Changzheng Hospital respectively. From October 2005 to October 2012, she served as the medical manager of the research and development department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States.

From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd. Dr. Zou enrolled into the department of clinical medicine at the Fourth Military Medical University in 1989 and graduated with a bachelor's degree in clinical medicine in 1995. She graduated with a doctorate degree in clinical oncology from the Second Military Medical University in August 2005.